Stephens analyst Sudan Loganathan initiated coverage of Bicycle Therapeutics (BCYC) with an Equal Weight rating and $25 price target as the firm is adding to its biotechnology research coverage with a focus on antibody-drug delivery technologies for the treatment of cancers. Bicycle has a proven platform of novel precision guided medicines to target cancers, but its lead assets have an “uphill battle to compete with incumbents,” the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Faces Strategic Risks from Concentrated Shareholder Influence
- Bicycle Therapeutics: Promising Q3 Results and Business Progress
- Bicycle Therapeutics reports Q3 EPS (74c), consensus (78c)
- BCYC Earnings this Week: How Will it Perform?
- Bicycle Therapeutics announces presentation of MT1-MMP data